NCT03854903 2025-02-06
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
Georgetown University
Phase 1 Completed
Clinical Trials
11 trialsNCT03023319 2022-06-14
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Augusta University
Phase 1 Completed
NCT04655391 2022-06-09
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
City of Hope Medical Center
Phase 1 Withdrawn
NCT02782403 2020-11-19
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02058277 2014-06-24
A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
Pfizer
Phase 1 Completed
NCT01025570 2014-05-09
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
University of California, San Francisco
Phase 1 Terminated
NCT00195260 2013-02-11
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
Pfizer
Phase 1 Completed
NCT01374139 2011-11-30
Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects
Pfizer
Phase 1 Completed
NCT01001936 2009-10-27
Study Evaluating SKI-606 in Subject With Solid Tumors
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Completed
NCT00759837 2009-07-16
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Completed
NCT00777530 2008-10-23
Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Completed